Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: Sofosbuvir plus daclatasvir for 12 weeks cures most HIV/HCV coinfected patients


Guru

Status: Offline
Posts: 1516
Date:
RE: Sofosbuvir plus daclatasvir for 12 weeks cures most HIV/HCV coinfected patients
Permalink  
 


Pretty incredible stats!

I would imagine a virtual gold mine for anyone co-infected ...

I'm glad to see progress being made here.

Thanks for the article Jill!

 

Dave



__________________

63yy,HCV,2b,F3-A1, Sof/Riba,12wks Tx   SOT: 1/20/16, HCV-RNA 9,816,581, ALT 56, Hb 14.6

4wk: HCV-RNA <15 Detected, ALT 15, AST 17, Hb 13.6 EOT: 4/12/16, ALT 18 , Hb 12.9176a2f85d05d9c965eafe199f2ba9ba5.jpg SVR Achieved 7/8/16

 



Guru

Status: Offline
Posts: 5599
Date:
Permalink  
 

Nearly all HIV/HCV coinfected patients treated for 12 weeks with an interferon- and ribavirin-free regimen of sofosbuvir (Sovaldi) and daclatasvir (Daklinza) achieved sustained virological response, but the cure rate fell to 76% for those treated for only 8 weeks, according to results from the ALLY-2 trial presented at Digestive Disease Week 2015 last month in Washington, DC.

Kenneth Sherman of the University of Cincinnati presented findings from the phase 3 ALLY-2 trial, which evaluated Gilead Sciences' nucleotide polymerase inhibitor sofosbuvir plus Bristol-Myers Squibb's NS5A inhibitor daclatasvir without ribavirin.  Daclatasvir is pangenotypic - meaning it works against multiple HCV genotypes - unlike ledipasvir, the NS5A inhibitor in Gilead's Harvoni coformulation.

Sherman reported that 96% of genotype 1 treatment-naive patients and 98% of treatment-experienced patients treated for 12 weeks achieved sustained virological response, or undetectable HCV RNA 12 weeks after completing treatment (SVR12).  The sustained response rate fell to just 76%, however, for genotype 1 treatment-naive patients treated for only 8 weeks.

Response rates were similar when looking at all genotypes combined.  Everyone with genotype 2, 3 or 4 who was treated for 12 weeks achieved SVR12.

People with cirrhosis had somewhat lower cure rates than non-cirrhotic patients in both the 8-week arm (60% vs 77%) and in the 12-week arms (91% vs 99%).

 

Full article...

http://www.aidsmap.com/Sofosbuvir-plus-daclatasvir-for-12-weeks-cures-most-HIVHCV-coinfected-patients/page/2973850/



__________________

Jill 

(68 yo, lives in UK)

Was Gen 3a, 

24wks Peg/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.